Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C34H49N7O8 |
| Molecular Weight | 683.795 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]3CCC(=O)N3)C(O)=O
InChI
InChIKey=RFDMQNKNNCOSFL-FWEHEUNISA-N
InChI=1S/C34H49N7O8/c1-2-3-4-5-6-14-29(43)36-17-10-9-13-25(34(48)49)39-32(46)26(18-21-20-37-23-12-8-7-11-22(21)23)40-33(47)27(19-28(35)42)41-31(45)24-15-16-30(44)38-24/h7-8,11-12,20,24-27,37H,2-6,9-10,13-19H2,1H3,(H2,35,42)(H,36,43)(H,38,44)(H,39,46)(H,40,47)(H,41,45)(H,48,49)/t24-,25-,26-,27-/m0/s1
SIS Shulov Innovative Science is developing ZEP 3, a short synthetic peptide. This drug was studied in phase II clinical trial for the treatment of cold sores (Herpes labialis). In addition, was shown that ZEP-3 exhibited analgesic activity in various indications such as osteoarthritis, herpes labialis and ocular pain. In parallel, the company is planning a phase II clinical study in atopic dermatitis.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1026276-22-1
Created by
admin on Sat Dec 16 12:09:19 GMT 2023 , Edited by admin on Sat Dec 16 12:09:19 GMT 2023
|
PRIMARY | |||
|
0L93DJI2CP
Created by
admin on Sat Dec 16 12:09:19 GMT 2023 , Edited by admin on Sat Dec 16 12:09:19 GMT 2023
|
PRIMARY | |||
|
9896260
Created by
admin on Sat Dec 16 12:09:19 GMT 2023 , Edited by admin on Sat Dec 16 12:09:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
